Health
For Seniors with IBD, Think Safety with Treatments – MedPage Today
Hospitalizations risks were lower with vedolizumab than TNF inhibitors
Among older adults with inflammatory bowel disease (IBD), vedolizumab (Entyvio) appeared to be safer than tumor necrosis factor (TNF) inhibitors, a large retrospective study suggested.
After weighting using standardized mean differences, new users of vedolizumab had a lower likelihood of all-cause hospitalization during the 12 months after initiating biologic treatment compared with those starting TNF inhibitors, with a hazard ratio of 0.81 (95% CI 0.68-0.96), according to Bharati Kochar, MD, of…
-
Noosa News20 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
Business23 hours ago$10,000 invested in ANZ shares 5 years ago is now worth…
-
Noosa News22 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
General21 hours agoInternal Revenue Service starts cutting 20,000 workers